Electromed, Inc. (ELMD) Earnings Call Transcript
February 10, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and thanks for being on this earnings call for Electromed, Inc. Financial results for 2026Q2 were issued by Electromed, Inc. earlier today. You can find that press release right now on the company's website, www.smartvest.com. Before we begin, I want to remind all of you that certain remarks management makes during this call are deemed forward-looking statements, which includes comments regarding the company's future operating and financial results and plans. Risks and uncertainties apply to such statements, and those could lead to actual performance or achievements differing materially from what was projected. Management's expectations as of today's date are represented by any such statements. Undue reliance should not be placed on those forward-looking statements, and no obligation is undertaken by the company to update or revise forward-looking statements, whether from new information, future events, or otherwise. For additional guidance on this matter, please refer to the company's SEC filings. With me on today's call are Jim Cunniff, Electromed's President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer. Consistent with prior calls, operational highlights from the quarter will be provided by Jim, the financials will then be reviewed by Brad, and a question and answer session will close us out. With that, I'll hand the call over to Jim Cunniff, President and Chief Executive Officer of Electromed, Inc.
Good afternoon, everyone, and thanks for being on the call with us today. I'm delighted to report strong results for the quarter that closed on December 31, 2025. Before we get into the figures, I'm happy to say this is our thirteenth straight quarter in which revenue and profit grew compared with the prior-year period. That accomplishment demonstrates how solid our business model is and shows that our best-in-class SmartVest airway clearance solution is gaining ever more recognition. Now let me walk through a few financial highlights from fiscal Q2. Revenue hit a record $18.9 million, which works out to robust growth of 16.3% versus the same period a year earlier. On the quarter, our growth was fueled by steady, robust results in the core Home Care segment, which climbed 18.4% compared with a year earlier, plus our distributor channel, where sales rose 12.1% versus the prior-year period. What these figures demonstrate is that our sales approach is delivering and that our valued home medical equipment partners continue to generate increasing demand. Meanwhile, the hospital channel recorded a 9.4% year-over-year drop for the quarter, a consequence of deliberately giving shipment priority to high-demand home patients and the irregular timing of capital orders. Looking forward, we anticipate hospital demand will recover over the coming quarters. On top of that revenue growth, operating income for the quarter reached $3 million, representing strong year-over-year expansion of 42.4%. We achieved an operating margin of 19% of sales, which is quite a strong result, and we continue to show operating leverage. Fully diluted earnings per share came in at $0.32, compared with $0.22 per share in 2025. Our balance sheet is still in great shape, with $13.8 million of cash on hand and zero debt. Back in Q1, as we shared before, the board gave approval for a $10 million stock repurchase authorization. That decision shows our belief in what lies ahead for Electromed, Inc., as well as our dedication to creating shareholder value. Let me now turn to our strategic initiatives and the opportunities in the market. Most of you are aware that the biggest strategic opportunity for Electromed, Inc. is in serving the bronchiectasis market, which remains vastly underserved. Right now in America, roughly 923,000 people have received a bronchiectasis diagnosis. But just 16% of them are getting the benefits of high-frequency chest wall oscillation therapy at this time. That leaves an amazing, untapped chance to serve close to 800,000 diagnosed individuals who stand to gain life-changing results from our SmartVest system. And what's even more thrilling, projections suggest more than 4 million others may have bronchiectasis without knowing it, which underscores how enormous the demand is for education and for building awareness around this serious health issue. To capture this opening, during calendar 2025 we rolled out successfully our creative "Triple Down on Bronchiectasis" campaign, which champions a potent three-pronged treatment paradigm. First, you clear the airways using SmartVest, which does a good job getting rid of mucus — that mucus is what feeds later infections. Next, you give the patient antibiotics to address those infections. Then, third, you work on bringing inflammation down. Putting those three elements together disrupts a destructive cycle in which ongoing infection, inflammation that won't quit, and harm to the airways keep compounding, which drives worsening lung disease and makes life worse for patients. We keep looking for more ways to build awareness. During Q2, our marketing team attended 3 national trade shows along with numerous regional pulmonary medical events, and we co-promoted 3 virtual continuing education units that respiratory associates hosted, drawing 655 attendees, so we could showcase our technology and emphasize how essential airway clearance and bronchiectasis management really are. We wrapped up a major manuscript that used data from the NTM Bronchiectasis Research Registry. It found that 58% of patients who qualified met clinical criteria but were never prescribed HFCWO therapy — and those patients were notably sicker than people who didn't meet the criteria. That points to an obvious short-term chance to intervene earlier, and our committed team is making strong progress toward closing that gap. Beyond that, to expand how many patients can take advantage of our technology, we signed 25 payer contracts in the first half of our fiscal year, bringing an additional 2.9 million covered lives into the more than 270 million covered lives already under contract who could benefit from SmartVest. To make the most of what we're putting into marketing, we continue to build up a sales force that delivers strong results. At present, we have 58 skilled direct sales reps on board. By the close of this fiscal year, we intend to grow that figure to 61. Bringing on more reps is central to how we pursue growth, and it lets us connect with additional clinicians and patients through our innovative technology. On top of that, we're moving ahead impressively with the rollout of our Smart Order e-prescribe solution, which is enhancing the way prescribing clinics send orders to the team handling fulfillment. On previous calls, I've talked about how this digital tool does away with old-school fax workflows. It gives us full prescription records, which lets us get SmartVest to patients more quickly and smooths out how a clinic operates. During Q2, more than a third of incoming orders arrived via that platform, which shows how valuable it is. Our CRM, rolled out in Q1, is already producing great results — better productivity for field sales, sharper market intelligence, and easy coordination with the fulfillment group. The upshot is stronger sales output and an improved patient experience thanks to quicker, more efficient order processing. On top of that, early in this fiscal year we finished and put into place our plan to optimize manufacturing. To be more specific, we changed how our production floor is set up, which lets us build goods more efficiently and gives us more than enough room to accommodate expansion down the road. On the topic of production, it makes me very proud to point out that every part of Electromed, Inc.'s operations, including where products get put together, happens inside the United States, and the company itself calls the US home. On top of that, domestic sources account for 99% of our net revenues. Because of this, we can keep up our history of getting orders to customers when promised, all while holding gross margins at or above the mid-70% range. Tariffs keep showing up in headlines, and we stay watchful for any difficulties that might arise with our suppliers, who are mostly based here but could still face tariff-related issues further up their own supply chains. We believe that because our business is focused mainly on the United States, we're shielded from tariff effects and gain an edge over competitors. To wrap up, the second-quarter numbers show that Electromed, Inc. continues to produce outstanding outcomes under our growth strategy. We're expanding our market presence at a fast pace, strengthening our operational capacity, and posting impressive financial performance, and at the same time we're helping patients breathe with greater ease and enjoy an improved quality of life. With that said, I'd like to turn things over now to Brad Nagel, who will take us through the financial details. Brad, it's all yours.
Thanks, Jim. Every figure I'll go over relates to the 3 months that closed on December 31, 2025 — that's Q2 of fiscal 2026 — and is being compared against the 3 months that closed on December 31, 2024, which is Q2 of fiscal 2025. Net revenues rose 16.3% to $18.9 million, climbing from $16.3 million. Our direct home care business saw revenue rise 18.4% to $17.3 million, climbing from $14.6 million. That revenue gain came mainly from more direct sales along with greater net revenues for each sales representative. During Q2, our average was 58 home care direct field sales representatives. For Q2, annualized home care revenue for each weighted average direct sales representative came to $1.2 million, which is above the $1 million to $1.1 million per rep target range at Electromed, Inc. Non-home care revenue came in at $1.6 million. Home care distributor revenue climbed 12.1%, reaching $900,000 during the quarter. Hospital revenue was $700,000, a drop of 9.4%, while other revenue was $100,000, a decline of 52.3%. Gross profit rose year-over-year to $14.8 million, which is 78.4% of net revenues, versus $12.6 million, which was 77.7% of net revenues. Those gains in gross profit dollars and gross profit percentage came mainly from higher overall revenue along with greater net revenues for each device. Selling, general, and administrative, or SG&A, expenses totaled $10.8 million, which is up $1 million, or 10%. What drove that increase in the current period was mainly higher salaries and incentive compensation tied to a larger average number of sales headcount plus greater overall compensation cost. Operating income was $3.6 million, or 19.2% of net revenues, versus $2.5 million, or 15.6% of net revenues. That 42.4% rise in operating income came mainly from the gains in revenue and gross profit. Net income rose 40.3% to $2.8 million, or $0.32 per diluted share, versus $2 million, or $0.22 per diluted share. At December 31, 2025, Electromed, Inc. held $13.8 million in cash along with $26.3 million in accounts receivable and carried no debt, reaching a working capital of $36.2 million and total shareholders' equity of $45.4 million. That cash balance represents a $1.5 million decrease across the 6 months ended December 31, 2025, versus a $200,000 increase in cash across the 6 months ended December 31, 2024. What drove the cash decrease across the 6 months ended December 31, 2025, was mainly $3.2 million of positive operating cash flow, offset by $3.8 million of share repurchases of Electromed, Inc. common stock. To wrap up, we're pleased with the strong performance during the first half of our fiscal year and keep seeing chances to deliver on our objectives of double-digit top-line growth and expanded operating leverage, both across the quarters ahead and full fiscal year 2026. With that, we'd like to move to the Q&A portion of the call. Operator, please open the call to questions.
Hey Jim and Brad. Fantastic numbers. I appreciate you letting me ask. So to start, it seems the home care Medicare piece did especially well during this quarter, climbing a lot from the prior period. Is there anything worth mentioning there?
Nope. I'd say we're simply carrying out our plan, Kyle. And thank you for asking, incidentally. As you're aware, we've strengthened our sales team gradually, and I believe the payoff is beginning to show in terms of the revenue we're seeing from home care. I'd add that, as we've mentioned on earlier calls, awareness of bronchiectasis has grown considerably in this area; what follows from that is that a growing number of prescribing doctors are beginning to spot patients who might do well with high-frequency chest wall oscillation technology; and, when you combine that with our sales reps visiting those accounts, assisting in finding patients who could gain from our technology, plus our clinician base that I believe is more aware that certain patients may have bronchiectasis, it makes for a strong mix. And, yes. So we're very pleased with what we've achieved not just in Q2 of this year but in the opening half of this year too.
Yep, understood. That tracks. And on a similar note, when it comes to raising awareness about bronchiectasis, as you're aware, Brent Supri's sales during its first full quarter reached $145 million, which is quite impressive. I'd say it's among the best respiratory launches ever. Could you share how this is affecting your business and helping to raise awareness for HFCWO?
Excellent question. I believe everyone was curious about what bransupri's launch would do to this space, since it's the first FDA-approved drug for treating bronchiectasis; however, our view is that it truly serves as a complement to airway clearance. As you know, Kyle, bronchiectasis is unfortunately chronic. It can't be reversed. And one of the difficulties these patients face is mucus accumulating in their airways, which they need to get rid of. The drug, brensoapri, for those listening who don't know it, actually targets one part of that vicious cycle, which is inflammation. But once again, bronchiectasis is chronic and cannot be reversed; you need something that clears the airways. That's precisely where SmartVest fits in; from our standpoint, they've done an excellent job educating people and drawing attention to this terrible disease. Consequently, as you pointed out in your question, they had an amazing Q4 for their drug. But we did too. So we believe the narrative we've been sharing about these being complementary is genuinely beginning to show up in the results.
Understood. I believe during your prepared remarks you brought up registry information indicating that 58% of patients eligible for HFCWO therapy aren't getting it. Meaning those with a CT scan, a daily productive cough lasting six months, and who've tried and failed another option — yet no prescription has been written. From your perspective, with the new drug now on the market, do you believe more individuals are getting an accurate diagnosis? Or do you think, for bronchiectasis, that those being diagnosed are being appropriately set up for that? Or is it some mix of both? Just attempting to grasp how this might affect the use of HFCWO throughout the industry.
I'd say you've captured it perfectly. One of the difficulties for this patient population has been all those reimbursement requirements you just listed — daily productive cough, CT scan, tried and failed something else. Part of the issue, I think, hasn't just been awareness of bronchiectasis as a disease and recognizing it in patients, as you pointed out, Kyle, but also getting patients onto the technology earlier in their clinical journey instead of later. That 58% I cited in our notes truly highlights the fact that here's a group — this was a study done retrospectively involving more than 5,000 patients — and these individuals had bronchiectasis and met treatment guidelines, yet they still weren't provided the technology. So part of our task, and part of what we'll be promoting with our clinicians, is those results, because I believe it will shed light on the chance for us to get more patients onto our technology sooner rather than later.
Understood. Then perhaps only one additional item. I believe, let me check. Assuming an average of 58 home care direct reps, which I think spans 61 territories. Let me know if that's incorrect. Still, is 61 a solid figure? And how do you see this moving forward?
Yes. Yes. Yes. Regarding our productivity, I'd say we enjoyed a truly exceptional quarter, around $1.2 million per rep on an annualized basis. Once we reach 61 reps — and you're right, that's the number we're promoting for this fiscal year — my expectation is that our productivity per rep will likely settle in that million to million 1 range we've been guiding on. That's because, clearly, when a new rep is hired, training is required. They need time to get up to speed in the market. Relationships have to be built. So there's inevitably a lag in productivity when that occurs. The math simply bears out that we feel quite confident remaining within that million to million one for our sales rep productivity, which represents a vast improvement. Kyle, you've been covering us for quite some time. Compared to where we were, even several years ago.
Yes, I'm with you on that. It's really been something to see. So congratulations once more on how things turned out, and I appreciate you letting me ask.
Thanks a lot. I appreciate that.
Good afternoon, everyone, and thanks for taking my questions. To start, I'd like to build on what was said about rep productivity. Clearly, $1.2 million was a strong result. That said, as you move toward 61 reps — which works out to a 5% increase in rep headcount — is there any reason we should anticipate a drop of more than 5% from that $1.2 million figure, bringing it down into the $1 million to $1.1 million range? Or is that simply a level you feel more at ease with right now?
Yeah, thanks for asking, Ben. And yes, several different elements come into play when it comes to that rep productivity. Kyle actually touched on part of this with one of his questions. Factors such as our payer mix affect how much revenue each referral brings in, and that can push the figure up somewhat. So when a quarter like Q2 brings stronger growth in Medicare — the payer with the highest value for us — rep productivity comes in a bit higher. On the efficiency front, we've been clear that the CRM still isn't in place, and our plan is to keep building on the improvements the system has already delivered, so that we go on realizing more efficiency from the rep. That said, certain pricing pressures may also come into play, and that's the reason our guidance remains at $1 million to $1.1 million for each rep.
All right, understood. Now, regarding that mix — I mean, during the opening half of this fiscal year, growth among government payers has been amazing. Is there anything to say about commercial payers? From a quick glance, it seems like the pace is two or even three times higher. Did anything unusual happen with commercial or government payers that deserves a mention?
Not truly; clearly, while we're making sales, payer mix isn't something we seek out. Our focus out there is generating referrals; and across time we've noticed volatility in that area. At times Medicare expands somewhat quicker. At other times commercial payers expand quicker, yet there are no major patterns we'd highlight, going forward. That would suggest continued disproportionate expansion from either group versus the other, when we look toward the quarters ahead.
The sole point I'd tack onto what you said, Ben, is this: during our prepared remarks, we noted that 25 contracts got signed, all of them involving private pay. That translates into roughly 2.9 million possible patients joining our roster. Naturally, bronchiectasis doesn't affect every single one of them, but as Brad pointed out, in places where payer coverage was absent previously, our sales reps concentrate hard on finding people living with this disease who stand to gain from our technology. It gets difficult whenever a referral comes in for such a patient yet they sit outside our network. So the real chance before us is determining whether that out-of-network gap can be closed, letting us bring more patients onto the technology sooner instead of later.
That's clear to me. Of course, if you look at several quarters back, the situation was reversed — commercial was expanding at a quicker pace compared to government pay. And finally, from my side, I'm just wondering how frequently the board tends to take another look at the share buyback — its size and how quickly repurchases happen.
Right. So, looking at our actions during the prior year, we gave the green light to a pair of distinct tranches, each $5 million, spread across that year; yet in practice, the entire $10 million was bought back at a fairly steady rate throughout the year, with some quarter-to-quarter ups and downs. This year is no different; we approved the complete $10 million during Q1 and we constantly keep watching our cash situation, where the share price stands, and ways to act opportunistically so that our cash and our shareholders get the greatest possible value.
Given the five and five from last year, is ten and ten what we should be expecting for this year?
Yes. At the start of this year, we authorized $10 million.
But that starts up after June, correct?
That's not something we can guarantee. Once more, we're continuously evaluating ways to deploy our cash, though we're thrilled to be in year two, having approved an additional $10 million for this year.
All right, that's excellent. Well, I appreciate you fellows answering our questions, and congratulations on the quarter.
Thank you, Ben. I appreciate that.
Okay, thanks everybody for being here as we wrap up the earnings call for the second quarter of fiscal 2026. I really want to stress just how enthusiastic I feel about where Electromed, Inc. is headed and what lies ahead. We posted our thirteenth straight quarter in which revenue and profit rose compared with the same period a year earlier, along with better operating leverage. The initiatives we've put in place strategically are producing outstanding outcomes as we serve a sizable, underserved group of BE patients across the United States. Sitting on $13.8 million in cash, carrying no debt, and holding our stock repurchase authorization, we are putting money into growth while also returning value to those who own our shares. I'd like to express gratitude to our remarkable team for their commitment, to our customers for placing their confidence in us, and to our shareholders for sticking with us. I'm eager to keep building on the momentum we have in the coming quarters. Thanks so much, everyone.
That brings us to the end of this call. We appreciate you joining us for today's presentation. You're welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Electromed, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Electromed, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.